Previous Close | 0.0033 |
Open | 0.0029 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0029 - 0.0032 |
52 Week Range | 0.0020 - 0.0191 |
Volume | |
Avg. Volume | 991,663 |
Market Cap | 502,486 |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | Aug 12, 2020 - Aug 17, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Glen Rock, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx”) and ResolutionRx Ltd (“ResolutionRx”), collectively “RespireRx” and its subsidiaries and business units are referred to in this press release as the “Company.” ResolutionRx, an unlisted public Australian company, (Australian Company Number or ACN: 664 925 651) and a wholly-owned subsidiary of RespireRx, and RespireRx are pleased to jointly announce that on May 18, 2023, Resoluti
RespireRx Pharmaceuticals chief scientific officer Arnold Lippa joins Proactive's Natalie Stoberman to share details of the company's latest collaboration with University College London to study th...
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the entering into a material transfer agreement with University College London (UCL) as part of a collaborative research effort involving Dr. Ian Coombs and Prof. Mark Farrant, founder members o
Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the Company’s lead GABAkine. Like KRM-II-81, these analogs enhance GABAergic ne
Glen Rock, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased to announce that on March 22, 2023, Mr. Joseph Siegelbaum was appointed to the Board of Directors as an independent director. This press release contains forward looking statements. Please carefully read the sections below entitled “Not a Securities Offering” and “Cautionary Note Regarding Forward-Looking Statements.” Mr. Siegelbaum was a partner at the law fir
RespireRX Pharmaceuticals chief financial officer Jeff Margolis joins Proactive's Natalie Stoberman with the news that subsidiary ResolutionRX has announced a services agreement with Australian con...
Glen Rock, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- ResolutionRx Ltd (“ResolutionRx”), an unlisted public Australian company, (Australian Company Number or ACN: 664 925 651, Australian Business Number or ABN: 17 664 925 651) and a wholly-owned subsidiary of RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx”) are pleased to jointly announce that on February 27, 2023, ResolutionRx entered into a services agreement (“Services Agreement”) for clinical research and other related services with iN
ResolutionRx Director Arnold Lippa joins Natalie Stoberman from the Proactive studio to discuss its recent letter of intent for financing with Radium Capital.
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on January 27, 2023, ResolutionRx Ltd (“ResolutionRx”), a newly formed Australian unlisted public company, and initially, a wholly-owned subsidiary of RespireRx, entered into a Letter of In
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Company and the Board of Trustees of University of Illinois, a body corporate and politic of the State of Illinois (“UIL”), have agreed to a second amendment (“Second Amendment”) to thei
Glen Rock, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on January 11, 2023, it established ResolutionRx Ltd (“ResolutionRx”), a new, currently wholly-owned, unlisted public company in Australia, as the first in a series of steps that include, b
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that RespireRx has been accepted into the NIH HEAL Initiative® NINDS Preclinical Screening Platform for Pain (PSPP) program. The Company’s lead GABAkine, KRM-II-81, has been shown to be effective
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on November 14, 2022, the Company entered into a letter of intent (“LOI”) with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic cl
Glen Rock, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Jeff Margolis, Senior Vice President, Chief Financial Officer, Treasurer and Secretary is presenting a summary and update about the Company at the Investor Summit Q4 sponsored by the Investor Summit
Glen Rock, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Dr. Arnold Lippa, Chief Scientific Officer, Executive Chairman of the Board and Interim President and Interim Chief Executive Officer is an invited speaker and panel moderator at the 5th Meridian Dr
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Sleep Review Magazine has published, in its June 13, 2022 edition, a free e-book entitled “How Close Are We to Drug Therapy for Obstructive Sleep Apnea?”, in which it discusses the RespireRx dronabi